PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell

PD-1 inhibitor Keytruda combined with chemotherapy for Triple-negative breast cancer (TNBC) has been approved for FDA, successfully representing the combination therapy of immunotherapy and chemotherapy for the first time in 2020. However, PD-L1 inhibitor Tecentriq combined with albumin paclitaxel u...

Descripción completa

Detalles Bibliográficos
Autores principales: Zha, Hualian, Xu, Zhanxue, Xu, Xichao, Lu, Xingyu, Shi, Peilin, Xiao, Youmei, Tsai, Hsiang-I, Su, Dandan, Cheng, Fang, Cheng, Xiaoli, Chen, Hongbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229990/
https://www.ncbi.nlm.nih.gov/pubmed/35745835
http://dx.doi.org/10.3390/pharmaceutics14061263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229990/
https://www.ncbi.nlm.nih.gov/pubmed/35745835
http://dx.doi.org/10.3390/pharmaceutics14061263

Ejemplares similares